Connect with us

Crypto

Major Biotech Company Windtree Embraces Crypto: Plans Bitcoin Payments and Digital Asset Treasury Strategy

Published

on

Major Biotech Company Windtree Embraces Crypto: Plans Bitcoin Payments and Digital Asset Treasury Strategy

Windtree intends to accept cryptocurrency as an option for payment and also to hold as an asset

WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions and diseases, announced that its Board of Directors has agreed that the Company will create a cryptocurrency policy that will allow the Company to accept cryptocurrency as an option for payment and also allow the Company to hold the cryptocurrency as an asset.

The Company’s cryptocurrency policy is intended to align with innovative digital commerce trends where millions of people hold cryptocurrency. If a payment is made to the Company with cryptocurrency in its revenue generating business, it can be held long term as a potential strategic asset.

“Windtree is executing our new corporate strategy to become a revenue generating company and we are in discussions with several groups that focus on Bitcoin and other cryptocurrencies as an option for payment. These companies are interested in furthering a treasury strategy in conjunction with Windtree and its current diversified operations base. Our Company can also hold the cryptocurrency as an asset,” said Jed Latkin, CEO of Windtree. “Our Board is supportive of this opportunity and our development of a cryptocurrency policy which we expect to be completed in the near term.”

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.

Advertisement

Forward Looking Statements
This press release contains statements related to. Such statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to acquire revenue generating subsidiaries; the market’s reaction to potential acquisitions by the Company; the Company’s ability to secure significant additional capital as and when needed; the Company’s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact Information:
Eric Curtis
ecurtis@windtreetx.com

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Crypto

The Last Frontier For Cryptocurrency Adoption

Published

on

The Last Frontier For Cryptocurrency Adoption

While studies reveal institutional investors and wealth managers believe tokenized ETFs will drive mainstream market adoption for cryptocurrency, there looms the theft of bad actors that most often go untraceable.

Barriers to the expansion of tokenization are starting to fall as major investment firms consider launching tokenized ETFs, according to new global research by London-based Nickel Digital Asset Management (Nickel), Europe’s leading digital assets hedge fund manager founded by alumni of Bankers Trust, Goldman Sachs and JPMorgan.

Its study with institutional investors (pension funds, insurance asset managers and family offices) and wealth managers at organisations which collectively manage over $14 trillion in assets found almost all (97%) believe the potential launch of tokenized ETFs such as BlackRock’s will be important to the expansion of the sector with nearly one in three (32%) rating the development as very important.

The study also reflected the belief that tokenization will continue to grow, with nearly 70% of respondents believing that fund managers looking to tokenize investment funds and asset classes will increase over the next three years.

Advertisement

Nickel’s research with firms in the US, UK, Germany, Switzerland, Singapore, Brazil and the United Arab Emirates found growing awareness of the benefits of tokenization. Private markets are seen as offering the greatest potential for tokenization, with almost 70% seeing private equity funds as the asset class with the most opportunity, followed by fixed income (55%) and public equities (42%).

Anatoly Crachilov, CEO and Founding Partner at Nickel Digital, said: “Tokenization is quickly moving from theory to real-world adoption as institutional investors grow more comfortable with its benefits and see major players enter the space. When firms like BlackRock step in, it fundamentally shifts the conversation. This development is timely for our multi-manager vehicle as expanding liquidity depth will allow some of our pods to start trading tokenized assets in the coming months.”

To address potential criminal threat, an advanced detection system to identify and trace blockchain funds connected with criminal activity was presented earlier this week at the Annual CyberASAP Demo Day in London.

The system, called SynapTrack, enables faster and more accurate detection of fraudulent activity using blockchains and cryptocurrencies, where traditional anti-money laundering and counter-terrorist financing systems struggle to keep pace.

Although current fraud detection methods pick up unusual activity, they deliver an extremely high rate (40%) of false positive reports. These require manual checking by compliance professionals, resulting in backlogs in identifying and acting on suspicious activity.

Advertisement

The SynapTrack system is designed to deliver a substantially lower rate of false positives. It has already been tested using real-life data from the notorious 2025 Bybit hack, where criminals stole $1.5bn of digital tokens from a cryptocurrency exchange. SynapTrack traced the hacker with 98% accuracy.

The team behind SynapTrack is keen to hear from exchanges, financial regulators or law enforcement agencies who want to test the prototype in real-world conditions.

SynapTrack uses a validated methodology to score the likelihood of transactions being part of a money laundering scheme. It has a self-improving algorithm that continuously adapts to new tactics – dynamically identifying suspicious patterns in blockchain transactions. It has a universal cross-chain capability, and is designed around how compliance teams work, presenting results in a dashboard. No infrastructure changes are needed for installation.

It is relatively easy to obscure fraudulent or criminal activity by moving funds between blockchains, or dispersing them across many blockchains, in what are known as ‘cross-chain’ transactions. It is these transactions that pose the greatest difficulty for existing anti-money laundering systems.

SynapTrack was developed by University of Birmingham computer scientists Dr Pascal Berrang and PhD student Endong Liu, in collaboration with blockchain developer Nimiq. Dr Berrang’s research is in IT security and privacy on blockchain, artificial intelligence and machine learning. The subject of Endong Liu’s PhD is transaction tracing. Nimiq is supporting with blockchain-specific insights, knowledge of real-world constraints, and implementation.

Advertisement

The team is currently fundraising to ensure regulatory readiness and complete the team with a CEO and software developers.

Dr Berrang said: “The last few years have seen a near-exponential growth in blockchain transactions. While many of these are legitimate, blockchains are attractive to criminals as funds can be moved very quickly to other jurisdictions. Our work with Nimiq and the creation of SynapTrack is addressing this black spot, and will enable more effective regulation, making the whole ecosystem of blockchain safer and more trustworthy.”

With the financial market and cybersecurity industry converging, cryptocurrency is here to stay.

Continue Reading

Crypto

Bitcoin drops to $63,000 as U.S. and Israel launch strikes on Iran

Published

on

Bitcoin drops to ,000 as U.S. and Israel launch strikes on Iran

Bitcoin briefly reclaimed $65,000 before pulling back to $64,700 as the Iran conflict continued to escalate through Saturday.

Iranian state media reported at least 70 killed in its Hormozgan province, per Aljazeera, including a strike on an elementary school. Israel activated air raid alerts after detecting fresh missile launches from Iran.

Trump told the Washington Post that “all I want is freedom for the people.” NATO said it was “closely following” developments, China urged an immediate ceasefire, and Turkey offered to mediate.

Bitcoin’s inability to hold $65,000 on the bounce suggests sellers remain in control, but the relative stability given the severity of the headlines points to thin weekend order books rather than active selling pressure.

Headline risks persist for BTC traders as the U.S. day progresses.

Advertisement

What happened earlier

Earlier in the day, BTC neared $63,000 in Saturday trading after the U.S. and Israel launched military strikes on Iran, pushing the largest cryptocurrency down roughly 3% in a matter of hours and extending what had already been a difficult weekend for risk assets.
The move brought bitcoin to its lowest level since the Feb. 5 crash, when the token briefly dipped below $60,000.

Israeli Defense Minister Israel Katz declared an immediate state of emergency across all areas of Israel. A U.S. official confirmed American participation in the strikes, The Wall Street Journal reported.

The sell-off follows a well-established pattern. Bitcoin trades 24 hours a day, 7 days a week, while equity and bond markets are closed on weekends.

That makes it one of the only large, liquid assets available for traders to sell when geopolitical risk spikes outside of traditional market hours.

The result is that bitcoin often acts as a pressure valve for broader risk-off sentiment during weekend events, absorbing selling that would otherwise spread across equities, commodities, and currencies if those markets were open.

Advertisement

The attack risks a wider regional conflict in one of the most economically sensitive parts of the world, following a month-long U.S. military buildup and failed negotiations over Iran’s nuclear program.

Continue Reading

Crypto

Better Cryptocurrency to Buy With $5,000 and Hold Forever: XRP vs. Ethereum | The Motley Fool

Published

on

Better Cryptocurrency to Buy With ,000 and Hold Forever: XRP vs. Ethereum | The Motley Fool

Both Ethereum (ETH 6.03%) and XRP (XRP 3.76%) are tried-and-tested blockchains which have survived (and sometimes thrived) for years on end. That means they’re both sturdy enough to be candidates for a big investment, like $5,000, and for holding over the very long term, or even forever.

So which of these two leading coins is the better option for a forever hold?

Image source: Getty Images.

Ethereum has more ways to grow

Forever is a long time, especially for an investment in an emerging sector like crypto. Therefore, an asset’s optionality regarding where it can derive growth is a key factor, as today’s growth drivers might peter out and new ones are likely to emerge.

On that front, Ethereum has plenty of options. It already hosts a large decentralized finance (DeFi) ecosystem worth more than $53 billion today, powered by a massive stablecoin base of $159 billion. That existing base of capital is a strategic asset because it gives developers and financial institutions a reason to build new products right where liquidity already lives. It also gives investors exposure to many possible growth lanes at once, from the onboarding of tokenized real-world assets (RWAs) to the development of new settlement rails for payments between AI agents.

Advertisement
Ethereum Stock Quote

Today’s Change

(-6.03%) $-123.58

Current Price

$1924.97

Another advantage is that Ethereum has a track record of consistently shipping large protocol upgrades. The Pectra upgrade, for example, landed on the mainnet in May 2025, followed by the Fusaka upgrade in December. Two similarly large feature packages are expected for 2026, and they should help to build the chain’s ability to scale up without spiking transaction costs.

If you plan to hold an asset indefinitely, this network’s culture of iterative improvement reduces the risk that its technical capabilities will become irrelevant as emerging opportunities for growth arise. Its habit of attracting and retaining substantial capital also helps prevent that outcome.

XRP has to keep winning specific fights over time

XRP is not a bad crypto asset by any means, but its long-term burden is its far narrower positioning than Ethereum.

Ripple, the coin’s issuer, built the XRP Ledger (XRPL) ecosystem as a toolkit of financial technologies to support specific workflows in institutional finance, especially cross-border payments and money transfers, and, more recently, the management of tokenized asset capital. The coin’s value is thus derived from the utility of its ledger.

Advertisement

That focus could pay off if the financial companies the chain targets like what it’s offering, but it also concentrates risk. Financial institutions move cautiously, and winning them over is a slow, grinding process of catering to their needs and building strong relationships. Their technology adoption process can stall for years, even when the product works, and decision-makers broadly want to adopt the new tech.

To Ripple’s credit, the XRP Ledger includes plenty of features that match institutional requirements and seek to minimize their potential pain points. The network’s authorized trust lines, for instance, let tokenized asset issuers whitelist who can hold their issued tokens, which is a feature that supports regulatory constraints around who can legally custody an asset. Similarly, the ledger supports freezing tokens when suspicious activity appears, which is a control that traditional finance teams tend to expect in regulated asset workflows.

XRP Stock Quote

Today’s Change

(-3.76%) $-0.05

Current Price

$1.35

Advertisement

But holding a coin forever is unforgiving of sustained competitive pressure, which XRP doubtlessly faces. Its competitors include fintech companies and other cryptocurrencies, not to mention the internal tech development capabilities of many of its target users in big banks. So it’ll need to continuously one up the other players in its space if it’s going to grow over the long term, and it’s hard to believe that it’ll win every round that counts.

The verdict

The decision here is about resilience and resources.

Advertisement

Ethereum’s “grizzled veteran” reputation today stems from surviving numerous shifts in user demand patterns while maintaining a large on-chain capital pool and growing it all the while. Its success or failure in any given crypto market segment is not guaranteed, nor was it in the past, but its constant evolution has ensured that failures are not fatal, and also that missed opportunities aren’t very damaging overall.

XRP, on the other hand, is only just starting to scale up its on-chain capital base; it has only $418 million in stablecoins. Furthermore, while it has succeeded in attracting some financial institutions to its chain, the truth is that its growth trajectory has not yet been seriously tested, and is still finding an appropriate product-market fit. Its real competitive challenges have only just begun.

So if you want a coin to buy with $5,000 and hold forever, pick the asset that can win without needing to be perfect: Ethereum. XRP is still a decent long-term hold, assuming it’s part of a diversified crypto portfolio, but it’s riskier.

Continue Reading

Trending